The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global proteomics market exhibited strong growth during 2015-2020. Looking forward, IMARC Group expects the market to grow at a CAGR of 14.4% during 2021-2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
Proteomics refers to the study of proteomes, their structure and physiological functions on a large-scale. In 1994, Mark Wilkins first coined the term proteome for the proteins that are translated from genome, to denote the whole set of proteins synthesized within a living organism. It encompasses the modifications and alterations that take place in the existing protein when it is exposed to varying conditions. Proteomics applies various technologies for the quantification and identification of proteins, along with the detection of diagnostic markers, understanding of pathogens in cells and interpretation of protein pathways in different diseases. It also evaluates the rate of protein production and the interaction patterns of proteins due to which it finds extensive applicability in drug discovery and the development of personalized medications.
The growing preference for personalized drugs, along with increasing research and development in drug discovery and biotechnology, is the key factor driving the growth of the market. Proteomic systems reduce the time, cost and resources needed for the chemical synthesis and biological testing of drugs and simplify the process of drug discovery. Furthermore, opportunities related to biomarker identification and mass spectrometry-based proteomics are favoring the market growth further. Additionally, the market is driven by increasing technological penetration in the comprehensive analysis of protein techniques. These techniques include Electrospray Ionization-Liquid Chromatography-Mass Spectrometry (ESI-LC-MS), surface plasma resonance, microarray, protein fractionation systems and X-ray crystallography. These advancements enable a thorough quantitative and qualitative analysis of proteins and identification of cancer therapies and treatments. Other factors, such as favorable government policies for extensive research and development (R&D) are also augmenting the growth of the market.
Breakup by Analysis Type:
Breakup by Component Type:
Breakup by Technology:
Breakup by Application:
Breakup by End-User:
Breakup by Region:
The report has also analysed the competitive landscape of the market with some of the key players being Agilent Technologies Inc., Bio-RAD Laboratories Inc., Bruker Corporation, Creative Proteomics, Danaher Corporation, GE Healthcare Inc., Horiba Ltd., Luminex Corporation, Merck Group, Perkinelmer Inc., Promega Corporation, Thermo Fisher Scientific Inc., Waters Corporation, etc.
|Base Year of the Analysis||2020|
|Segment Coverage||Analysis Type, Component Type, Technology, Application, End-User, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||Agilent Technologies Inc., Bio-RAD Laboratories Inc., Bruker Corporation, Creative Proteomics, Danaher Corporation, GE Healthcare Inc., Horiba Ltd., Luminex Corporation, Merck Group, Perkinelmer Inc., Promega Corporation, Thermo Fisher Scientific Inc. and Waters Corporation|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2299
Five User License: US$ 3399
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
Key Questions Answered in This Report:
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at